The epilepsy drugs market size has the potential to grow by USD 2.13 billion during 2020-2024, and the market's growth momentum will accelerate during the forecast period.
This report provides a detailed analysis of the market by type (narrow-spectrum drugs and broad-spectrum drugs), etiology (genetic etiology, structural etiology, metabolic etiology, immune etiology, infectious etiology, and unknown etiology), age of onset (neonatal/infantile, childhood, adolescents/adults, and variable age), and geography (Asia, Europe, North America, and ROW). Also, the report analyzes the market's competitive landscape and offers information on several market vendors, including Abbott Laboratories, Eisai Co. Ltd., GlaxoSmithKline Plc, Johnson & Johnson, Mylan NV, Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., and UCB SA.
Market Overview
Browse TOC and LoE with selected illustrations and example pages of Epilepsy Drugs Market
Request a FREE sample now!
Market Competitive Analysis
The epilepsy drugs market is fragmented. Abbott Laboratories, Eisai Co. Ltd., GlaxoSmithKline Plc, and Johnson & Johnson are some of the major market participants. Factors such as the increasing prevalence of epilepsy, the growing use of specific and sensitive diagnostic modalities, and the rising patient awareness will offer immense growth opportunities. However, low safety profile of antiepileptic drugs, diverse epilepsy syndromes, and lack of cohesive care may impede market growth. To make the most of the opportunities, vendors should focus on growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
To help clients improve their market position, this epilepsy drugs market forecast report provides a detailed analysis of the market leaders and offers information on the competencies and capacities of these companies. The report also covers details on the market's competitive landscape and offers information on the products offered by various companies. Moreover, this epilepsy drugs market analysis report provides information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make the most of future growth opportunities.
This report provides information on the production, sustainability, and prospects of several leading companies, including:
- Abbott Laboratories
- Eisai Co. Ltd.
- GlaxoSmithKline Plc
- Johnson & Johnson
- Mylan NV
- Novartis AG
- Pfizer Inc.
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- UCB SA
Epilepsy Drugs Market: Segmentation by Geography
For more insights on the market share of various regions Request for a FREE sample now!
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. North America will offer several growth opportunities to market vendors during the forecast period.
57% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for epilepsy drugs in North America. This report provides an accurate prediction of the contribution of all segments to the growth of the epilepsy drugs market size.
You may be interested in the regional reports:
Europe Epilepsy Drugs market - The market share is positively influenced by the adoption of reformulation strategies by vendors and is expected to surpass US$ 1,100 million by 2019.
Epilepsy Drugs Market: Key Highlights of the Report for 2020-2024
- CAGR of the market during the forecast period 2020-2024
- Detailed information on factors that will drive epilepsy drugs market growth during the next five years
- Precise estimation of the epilepsy drugs market size and its contribution to the parent market
- Accurate predictions on upcoming trends and changes in consumer behavior
- The growth of the epilepsy drugs industry across Asia, Europe, North America, and ROW
- A thorough analysis of the market's competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of epilepsy drugs market vendors
We can help! Our analysts can customize this report to meet your requirements. Get in touch
Executive Summary
Market Landscape
- Market ecosystem
- Market characteristics
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2019
- Market outlook: Forecast for 2019 - 2024
Five Forces Analysis
- Five forces summary
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Type
- Market segments
- Comparison by Type
- Narrow spectrum drugs - Market size and forecast 2019-2024
- Broad spectrum drugs - Market size and forecast 2019-2024
- Market opportunity by Type
Segmentation by Etiology
- Genetic etiology
- Structural etiology
- Metabolic etiology
- Immune etiology
- Infectious etiology
- Unknown etiology
Segmentation by Age of Onset
- Neonatal/infantile
- Childhood
- Adolescents/adults
- Variable age
Customer landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2019-2024
- Europe - Market size and forecast 2019-2024
- Asia - Market size and forecast 2019-2024
- ROW - Market size and forecast 2019-2024
- Key leading countries
- Market opportunity by geography
- Market drivers
- Market challenges
- Market trends
Vendor Landscape
- Vendor landscape
- Landscape disruption
- Competitive Scenario
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- Abbott Laboratories
- Eisai Co. Ltd.
- GlaxoSmithKline Plc
- Johnson & Johnson
- Mylan NV
- Novartis AG
- Pfizer Inc.
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- UCB SA
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations